Lightelligence IPO Soars Over 400% in Hong Kong Debut Amid Rising AI Investment Demand 
Micro Systemation Reports Q1 Loss Amid Strategic Investments and Revenue Growth 
Air Liquide Q1 Revenue Misses Estimates Amid Currency and Energy Headwinds 
Nippon Express Stock Jumps as Elliott Investment Signals Strong Foreign Interest in Japan Logistics Sector 
Seagate Stock Surges After Strong Q3 Earnings Beat and Bullish Outlook 
Standard Chartered Q1 Profit Hits Record on Wealth and Investment Banking Growth 
WuXi AppTec Stock Surges on Strong Q1 Earnings and CRDMO Demand Growth 
Why Paycom Was Named a 2026 Platinum Employer on the Where You Work Matters List 
Amazon Stock Dips Despite Record Earnings as AI Infrastructure Spending Surges 
Microsoft Azure Growth Forecast Beats Expectations Amid Rising AI Competition 
China’s Ultra-Cheap EV Boom: Why Electric Cars Cost Far Less Than in the U.S. 
OpenAI Faces Revenue Pressure and User Growth Challenges Ahead of IPO 
Spirit Airlines Gains Key Creditor Support for $500M Bailout Deal 
Australia Targets Meta, Google, and TikTok With New News Payment Tax Proposal 
Ford Q1 Earnings Beat Expectations, Stock Surges on Strong Guidance 
T-Mobile Beats Q1 Earnings Expectations on Strong Postpaid Growth 
Pershing Square Raises $5 Billion in Landmark U.S. IPO and Share Placement 
WARREN, N.J., Feb. 03, 2016 -- Bellerophon Therapeutics, Inc. (Nasdaq:BLPH), a clinical-stage biotherapeutics company, today announced that it will participate in LEERINK Partners 5th Annual Global Healthcare Conference.
Jonathan Peacock, Bellerophon’s Chairman and Chief Executive Officer, will take questions during a fireside chat at 10:40 am ET on Wednesday, February 10, 2016.
A live webcast may be accessed under the investor tab at www.bellerophon.com. An archive of the presentation will be available following the presentation.
About Bellerophon
Bellerophon Therapeutics is a clinical-stage biotherapeutics company focused on developing innovative therapies at the intersection of drugs and devices that address significant unmet medical needs in the treatment of cardiopulmonary and cardiac diseases. The Company is currently developing two product candidates under its INOpulse program, a proprietary pulsatile nitric oxide delivery device. The first is for the treatment of pulmonary arterial hypertension (PAH), for which the Company intends to commence Phase 3 clinical trials shortly and the other for the treatment of pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD), which is in Phase 2 development. The Company is also planning to start testing the benefits of INOpulse for patients suffering from pulmonary hypertension associated with idiopathic pulmonary fibrosis (PH-IPF) for which results are anticipated by the end of 2016. For more information, please visit www.bellerophon.com.
Contact At Bellerophon: Amy Edmonds, Vice President Head of Clinical Operations & Administration (908) 574-4765 At Rx Communications Group: Melody Carey (917) 322-2571 [email protected]
